| Oct 21 |
LENZ Therapeutics Announces FDA Acceptance of New Drug Application for LNZ100 for the Treatment of Presbyopia
|
| Sep 30 |
LENZ Therapeutics Announces Presentations at Upcoming Ophthalmology and Optometry Medical Conferences
|
| Sep 27 |
Achieve, INmune, Lenz gain on bullish initiations from Raymond James
|
| Sep 12 |
LENZ Therapeutics Insiders Up US$178k On US$551.1k Investment
|
| Aug 30 |
LENZ Therapeutics: Upcoming PDUFA, Strong Data, Some Risks
|
| Aug 27 |
LENZ Therapeutics to Participate in Upcoming Investor Conferences
|
| Aug 16 |
LENZ Therapeutics, Inc. (LENZ) Q2 2024 Earnings Call Transcript
|
| Aug 14 |
LENZ Therapeutics, Inc. GAAP EPS of -$0.40 beats by $0.08
|
| Aug 14 |
LENZ Therapeutics Reports Second Quarter 2024 Financial Results
|
| Aug 12 |
LENZ Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for LNZ100 for the Treatment of Presbyopia
|
